Pyxis Oncology downgraded by William Blair
$PYXS
Biotechnology: Pharmaceutical Preparations
Health Care
William Blair downgraded Pyxis Oncology from Outperform to Mkt Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/5/2026 | $6.00 | Outperform | Wedbush |
| 11/3/2025 | $9.00 | Buy | Stifel |
| 9/4/2025 | $5.00 | Buy | Guggenheim |
| 11/21/2024 | Outperform → Mkt Perform | William Blair | |
| 11/8/2024 | $13.00 | Overweight | Stephens |
| 8/8/2024 | $10.00 | Buy | Stifel |
| 5/7/2024 | $10.00 | Buy | Jefferies |
| 2/9/2024 | $8.00 | Buy | BTIG Research |
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focused on patients treated at or below a dose cap Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in the first quarter of 2026 Updated data from MICVO Phase 1/2 dose escalation study in combination with pembrolizumab in 1L R/M HNSCC on track for the second half of 2026 Presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026 that support the clinical development of MICVO as both a monotherapy
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences: RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, May 19, 2026, fireside chat at 2:35 p.m. ET; andStifel Virtual Oncology Forum on Wednesday, May 20, 2026, fireside chat at 3:30 p.m. ET; andJefferies Global Healthcare Conference in New York, NY on Thursday, June 4, 2026, fireside chat at 7:35 a.m. ET. Live webcasts and replays of the fireside chats will be available on the Events & Presentations
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment of Nelson Azoulay as Chief Business Officer. Mr. Azoulay joins Pyxis Oncology with more than 15 years of experience in corporate strategy, business development, and value-creating transactions across the biopharma industry, including deep antibody-drug conjugate (ADC) experience. In his role, he will lead corporate development strategy and pursue strategic opportunities to advance MICVO, the Company's lead clinical asset. "We're excited to welcome Nelson to Pyxis Oncology," said Tom Ci
10-Q - Pyxis Oncology, Inc. (0001782223) (Filer)
8-K - Pyxis Oncology, Inc. (0001782223) (Filer)
DEFA14A - Pyxis Oncology, Inc. (0001782223) (Filer)
Wedbush initiated coverage of Pyxis Oncology with a rating of Outperform and set a new price target of $6.00
Stifel resumed coverage of Pyxis Oncology with a rating of Buy and set a new price target of $9.00
Guggenheim initiated coverage of Pyxis Oncology with a rating of Buy and set a new price target of $5.00
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
4 - Pyxis Oncology, Inc. (0001782223) (Issuer)
Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focused on patients treated at or below a dose cap Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in the first quarter of 2026 Updated data from MICVO Phase 1/2 dose escalation study in combination with pembrolizumab in 1L R/M HNSCC on track for the second half of 2026 Presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026 that support the clinical development of MICVO as both a monotherapy
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment of Nelson Azoulay as Chief Business Officer. Mr. Azoulay joins Pyxis Oncology with more than 15 years of experience in corporate strategy, business development, and value-creating transactions across the biopharma industry, including deep antibody-drug conjugate (ADC) experience. In his role, he will lead corporate development strategy and pursue strategic opportunities to advance MICVO, the Company's lead clinical asset. "We're excited to welcome Nelson to Pyxis Oncology," said Tom Ci
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026 Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track for mid-year 2026; to include patients treated with modified weight-based dosing and patients treated with total body weight dosing Updated data from MICVO Phase 1/2 dose escalation study in combination with KEYTRUDA® in 1L/2L+ R/M HNSCC on track for the second half of 2026 Announced appointment of Thomas Civik as Interim Chief Executive Officer Expected cash runway into the fourth quarter of 2026 BOSTO
46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kgUpdated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC expected mid-2026; updated data from ongoing Phase 1/2 study evaluating MICVO in combination with KEYTRUDA®, including in 1L/2L+ R/M HNSCC and other tumor types, expected 2H26 Company to host webcast and conference call today at 8:30 a.m. ET BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage comp
- Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30 p.m. ET - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. The Company ended the third quarter of 20
- Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. The Company ended the second quarter of 2024 with $157.2 million in cash, cash equivalents, restricted cash and short-term investments, which is expected
SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)
SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)
SC 13D/A - Pyxis Oncology, Inc. (0001782223) (Subject)